Teradyne (TER) Form 144 — 625 Shares to be Sold via Fidelity on 09/05/2025
Rhea-AI Filing Summary
Form 144 notice for Teradyne, Inc. (TER): The filer reports an intended sale of 625 common shares through Fidelity Brokerage Services on 09/05/2025 with an aggregate market value of $75,037.50. The securities were acquired by restricted stock vesting on 05/09/2024 and were received as compensation. The filing also discloses prior sales by the same person this year: 1,875 shares sold 07/30/2025 for $198,243.75 and 625 shares sold 08/05/2025 for $66,250.00. The filing states the seller represents there is no undisclosed material adverse information. The total shares outstanding reported are 159,073,532 and the planned sale is on NASDAQ.
Positive
- Clear compliance with Rule 144 reporting requirements including acquisition details and broker information
- Source of shares disclosed (restricted stock vesting) and sale execution channel specified (Fidelity Brokerage Services)
Negative
- Insider sales reported recently totaling 2,500 shares in the past two months, which may warrant monitoring for patterns
- Issuer name and some filer contact fields are blank in the provided tables, limiting contextual detail in the filing text
Insights
TL;DR Insider sale notice: small planned sale relative to shares outstanding; recent prior sales reported.
The Form 144 indicates routine disposition of equity awarded via restricted stock vesting. The planned 625-share sale valued at $75,037.50 is immaterial relative to the reported 159 million shares outstanding, suggesting limited direct impact on Teradyne's capitalization or market supply. Recent prior sales totaling 2,500 shares and proceeds disclosed provide context on ongoing insider liquidity. This filing is primarily a compliance disclosure rather than a material corporate event.
TL;DR Filing shows compliance with Rule 144 and disclosure of recent insider dispositions; no governance red flags in this notice alone.
The notice documents the source of shares (restricted stock vesting) and that sales are to be executed through an established broker, which aligns with standard insider sale procedures. The seller's representation about absence of undisclosed adverse information is standard. Without additional disclosures about issuer-specific events or larger-scale insider selling, this filing does not by itself raise governance concerns, though investors may track cumulative insider sales over time for pattern analysis.